Inhibrx Biosciences (INBX) EPS (Weighted Average and Diluted) (2023 - 2025)
Historic EPS (Weighted Average and Diluted) for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to -$2.28.
- Inhibrx Biosciences' EPS (Weighted Average and Diluted) rose 1971.83% to -$2.28 in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.4, marking a year-over-year decrease of 11040.34%. This contributed to the annual value of $112.62 for FY2024, which is 64992.64% up from last year.
- According to the latest figures from Q3 2025, Inhibrx Biosciences' EPS (Weighted Average and Diluted) is -$2.28, which was up 1971.83% from -$1.85 recorded in Q2 2025.
- In the past 5 years, Inhibrx Biosciences' EPS (Weighted Average and Diluted) registered a high of $125.48 during Q2 2024, and its lowest value of -$7.29 during Q4 2023.
- For the 3-year period, Inhibrx Biosciences' EPS (Weighted Average and Diluted) averaged around $9.08, with its median value being -$3.02 (2024).
- Per our database at Business Quant, Inhibrx Biosciences' EPS (Weighted Average and Diluted) surged by 301136.89% in 2024 and then crashed by 10147.43% in 2025.
- Quarter analysis of 3 years shows Inhibrx Biosciences' EPS (Weighted Average and Diluted) stood at -$7.29 in 2023, then soared by 56.18% to -$3.19 in 2024, then grew by 28.63% to -$2.28 in 2025.
- Its EPS (Weighted Average and Diluted) was -$2.28 in Q3 2025, compared to -$1.85 in Q2 2025 and -$2.8 in Q1 2025.